(2) nonpayment of claims submitted by the license holder for public program reimbursement; (3) recovery of payments made for the service; (4) disenrollment in the public payment program; or (5) other administrative, civil, or criminal penalties as provided by law. 245A.1915 OPIOID ADDICTION TREATMENT EDUCATION REQUIREMENT FOR PROVIDERS LICENSED TO PROVIDE CHEMICAL DEPENDENCY TREATMENT SERVICES. All programs serving persons with substance use issues licensed by the commissioner must provide educational information concerning: treatment options for opioid addiction, including the use of a medication for the use of opioid addiction; and recognition of and response to opioid overdose and the use and administration of naloxone, to clients identified as having or seeking treatment for opioid addiction. The commissioner shall develop educational materials that are supported by research and updated periodically that must be used by programs to comply with this requirement. 245A.192 PROVIDERS LICENSED TO PROVIDE TREATMENT OF OPIOID ADDICTION. Subdivision 1. Scope. (a) This section applies to services licensed under this chapter to provide treatment for opioid addiction. In addition to the requirements under Minnesota Rules, parts 9530.6405 to 9530.6505, a program licensed to provide treatment of opioid addiction must meet the requirements in this section. (b) Where a standard in this section differs from a standard in an otherwise applicable administrative rule, the standards of this section apply. (c) When federal guidance or interpretations have been issued on federal standards or requirements also required under this section, the federal guidance or interpretations shall apply. Subd. 2. Definitions. (a) For purposes of this section, the terms defined in this subdivision have the meanings given them. (b) “Diversion” means the use of a medication for the treatment of opioid addiction being diverted from its intended use. (c) “Guest dose or dosing” means the practice of administering a medication used for the treatment of opioid addiction to a person who is not a client of the program that is administering or dispensing the medication. (d) “Medical director” means a physician, licensed to practice medicine in the jurisdiction in which the opioid treatment program is located, who assumes responsibility for administering all medical services performed by the program, either by performing them directly or by delegating specific responsibility to authorized program physicians and health care professionals functioning under the medical director’s direct supervision. (e) “Medication used for the treatment of opioid addiction” means a medication approved by the Food and Drug Administration for the treatment of opioid addiction.
200
Made with FlippingBook - Online Brochure Maker